Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324401 · ClinicalTrials.gov registry record · NA
Oral Peanut Immunotherapy
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT01324401: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01324401 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01324401, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This research study is being done to develop an effective oral immunotherapy treatment for patients with peanut allergy.
Interventions
- DRUG Peanut flour OIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-03 |
| Est. Completion | 2018-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324401
The ClinicalTrials.gov registry entry for NCT01324401 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peanut flour OIT is the first listed.
NCT01324401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324401 about?
NCT01324401 is a clinical study titled "Oral Peanut Immunotherapy". Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This rese...
What is the current status of trial NCT01324401?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2011-03. Estimated completion is 2018-05.
What interventions are being tested in trial NCT01324401?
The interventions under investigation include: Peanut flour OIT (DRUG).
Who is sponsoring clinical trial NCT01324401?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.